Novartis India Limited has announced that its Board of Directors approved the acquisition of the trademarks 'Minipress' and 'Minipres' registered in India, alongside certain related intellectual property rights, from Pfizer Inc. USA and Pfizer Products Inc. USA. The transaction, backed by an asset purchase agreement and trademark assignment deeds executed simultaneously on September 7, 2026, involves a total aggregate consideration of Rs. 1,250 crore.

The acquired portfolio includes Minipress XL (prazosin), a medication primarily prescribed in India to treat hypertension and manage urinary symptoms caused by benign prostatic hyperplasia (BPH).

According to IQVIA MAT July 2026 data, Minipress XL recorded a revenue of Rs. 228.6 crore and has demonstrated a compound annual growth rate (CAGR) of 6.3% over the past four years, within a category growing at a 9% CAGR.